J. M. Levine, J. F. Kelvin, G. P. Quinn, and C. R. Gracia, Infertility in reproductive-age female cancer survivors, Cancer, vol.121, issue.10, pp.1532-1541, 2015.

C. Villarreal-garza, J. E. Bargallo-rocha, E. Soto-perez-de-celis, F. Lasa-gonsebatt, C. Arce-salinas et al., Realworld outcomes in young women with breast cancer treated with neoadjuvant chemotherapy, Breast Cancer Res Treat, vol.157, issue.2, pp.385-94, 2016.

D. Ribnikar, J. M. Ribeiro, D. Pinto, B. Sousa, A. C. Pinto et al., Breast cancer under age 40: a different approach, Curr Treat Options Oncol, vol.16, issue.4, p.16, 2015.

R. A. Anderson and D. A. Cameron, Pretreatment serum anti-Mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer, J Clin Endocrinol Metab, vol.96, issue.5, pp.1336-1379, 2011.

C. Bozza, F. Puglisi, M. Lambertini, E. O. Osa, M. Manno et al., Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients, Endocr Relat Cancer, vol.21, issue.1, pp.51-65, 2014.

N. Tomasi-cont, M. Lambertini, S. Hulsbosch, A. F. Peccatori, and F. Amant, Strategies for fertility preservation in young early breast cancer patients, Breast, vol.23, issue.5, pp.503-513, 2015.

F. J. Broekmans, M. R. Soules, and B. C. Fauser, Ovarian aging: mechanisms and clinical consequences, Endocr Rev, vol.30, issue.5, pp.465-93, 2009.

T. S. Domingues, A. M. Rocha, and P. C. Serafini, Tests for ovarian reserve: reliability and utility, Curr Opin Obstet Gynecol, vol.22, issue.4, pp.271-277, 2010.

S. L. Broer, F. J. Broekmans, J. S. Laven, and B. C. Fauser, Anti-mullerian hormone: ovarian reserve testing and its potential clinical implications, Hum Reprod Update, vol.20, issue.5, pp.688-701, 2014.

D. Dewailly, C. Y. Andersen, A. Balen, F. Broekmans, N. Dilaver et al., The physiology and clinical utility of antiMullerian hormone in women, Hum Reprod Update, vol.20, issue.3, pp.370-85, 2014.

C. Anders, P. K. Marcom, B. Peterson, L. Gu, S. Unruhe et al., A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer, Cancer Invest, vol.26, issue.3, pp.286-95, 2008.

R. A. Anderson, M. Rosendahl, T. W. Kelsey, and D. A. Cameron, Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer, Eur J Cancer, vol.49, issue.16, pp.3404-3415, 2013.

R. A. Anderson, A. P. Themmen, A. Al-qahtani, N. P. Groome, and D. A. Cameron, The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer, Hum Reprod, vol.21, issue.10, pp.2583-92, 2006.

A. M. D'avila, V. Biolchi, E. Capp, and H. Corleta, Age, anti-mullerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide, J Ovarian Res, vol.8, pp.82-89, 2015.

P. Hadji, A. Kauka, M. Ziller, K. Birkholz, M. Baier et al., Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study, Breast Cancer Res Treat, vol.144, issue.2, pp.343-51, 2014.

A. S. Hamy, R. Porcher, C. Cuvier, S. Giacchetti, M. H. Schlageter et al., Ovarian reserve in breast cancer: assessment with anti-Mullerian hormone, Reprod Biomed Online, vol.29, issue.5, pp.573-80, 2014.

N. L. Henry, R. Xia, A. F. Schott, D. Mcconnell, M. Banerjee et al., Prediction of postchemotherapy ovarian function using markers of ovarian reserve, Oncologist, vol.19, issue.1, pp.68-74, 2014.

L. Singh, K. Muttukrishna, S. Stein, R. C. Mcgarrigle, H. H. Patel et al., Predictors of ovarian reserve in young women with breast cancer, Br J Cancer, vol.96, issue.12, pp.1808-1824, 2007.

K. J. Ruddy, A. O'neill, K. D. Miller, B. P. Schneider, E. Baker et al., Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103, Breast Cancer Res Treat, vol.144, issue.3, pp.591-598, 2014.

H. C. Su, C. Haunschild, K. Chung, S. Komrokian, S. Boles et al., Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients, Cancer, vol.120, issue.23, pp.3691-3699, 2014.

H. I. Su, S. W. Flatt, L. Natarajan, A. Demichele, and A. Z. Steiner, Impact of breast cancer on anti-mullerian hormone levels in young women, Breast Cancer Res Treat, vol.137, issue.2, pp.571-578, 2013.

B. Yu, N. Douglas, M. J. Ferin, G. S. Nakhuda, K. Crew et al., Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy, Cancer, vol.116, issue.9, pp.2099-105, 2010.

S. M. Nelson, L. Marca, and A. , The journey from the old to the new AMH assay: how to avoid getting lost in the values, Reprod Biomed Online, vol.23, issue.4, pp.411-431, 2011.

R. A. Anderson and W. H. Wallace, Antimullerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer, Fertil Steril, vol.99, issue.6, pp.1469-75, 2013.

J. Chai, A. F. Howie, D. A. Cameron, and R. A. Anderson, A highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer, Eur J Cancer, vol.50, issue.14, pp.2367-74, 2014.

I. Ben-aharon, T. Granot, I. Meizner, N. Hasky, A. Tobar et al., Long-term follow-up of chemotherapy-induced ovarian failure in young breast cancer patients: the role of vascular toxicity, Oncologist, vol.20, issue.9, pp.985-91, 2015.

F. Lopes, R. Smith, R. A. Anderson, and N. Spears, Docetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing follicles, Mol Hum Reprod, vol.20, issue.10, pp.948-59, 2014.

H. S. Han, J. Ro, K. S. Lee, B. H. Nam, J. A. Seo et al., Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer, Breast Cancer Res Treat, vol.115, issue.2, pp.335-377, 2009.

A. M. Minisini, J. Menis, F. Valent, C. Andreetta, B. Alessi et al., Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era, Anticancer Drugs, vol.20, issue.6, pp.503-510, 2009.

W. B. Zhou, H. Yin, X. A. Liu, X. M. Zha, L. Chen et al., Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients, BMC Cancer, vol.10, p.281, 2010.

A. J. Chien, E. Duralde, R. Hwang, K. Tsung, C. N. Kao et al., Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer, Breast Cancer Res Treat, vol.153, issue.1, pp.173-81, 2015.

C. Silva, O. Caramelo, T. Almeida-santos, R. Rama, and A. C. , Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis, Hum Reprod, vol.31, issue.12, pp.2737-2786, 2016.

M. Hickey, M. Peate, C. M. Saunders, and M. Friedlander, Breast cancer in young women and its impact on reproductive function, Hum Reprod Update, vol.15, issue.3, pp.323-362, 2009.

E. Amir, O. Freedman, L. Allen, T. Colgan, and M. Clemons, Defining ovarian failure in amenorrheic young breast cancer patients, Breast, vol.19, issue.6, pp.545-553, 2010.

E. C. Larsen, J. Mü-ller, C. Rechnitzer, K. Schmiegelow, and A. N. Andersen, Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10 IU/l, Hum Reprod, vol.18, issue.2, pp.417-439, 2003.

C. Decanter, M. Peigne, A. Mailliez, F. Morschhauser, A. Dassonneville et al., Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimullerian hormone assay, Fertil Steril, vol.102, issue.2, pp.483-490, 2014.

J. Van-helden and R. Weiskirchen, Performance of the two new fully automated anti-Mullerian hormone immunoassays compared with the clinical standard assay, Hum Reprod, vol.30, issue.8, pp.1918-1944, 2015.

K. A. Phillips, I. M. Collins, R. L. Milne, S. A. Mclachlan, M. Friedlander et al., Anti-Mullerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations, Hum Reprod, vol.31, issue.5, pp.1126-1158, 2016.

R. Michaelson-cohen, P. Mor, N. Srebnik, U. Beller, E. Levylahad et al., BRCA mutation carriers do not have compromised ovarian reserve, Int J Gynecol Cancer, vol.24, issue.2, pp.233-240, 2014.

A. S. Hamy, R. Porcher, S. Eskenazi, C. Cuvier, S. Giacchetti et al., Anti-Mullerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies, Reprod Biomed Online, vol.32, issue.3, pp.299-307, 2016.

A. H. Partridge, K. J. Ruddy, S. Gelber, L. Schapira, M. Abusief et al., Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer, Fertil Steril, vol.94, issue.2, pp.638-682, 2010.